BUZZ-Contineum Therapeutics falls on planned $75 million share sale

Reuters12-12
BUZZ-Contineum <a href="https://laohu8.com/S/LENZ">Therapeutics</a> falls on planned $75 million share sale

** Drug developer Contineum Therapeutics' CTNM.O shares fall 2.5% to $12.74 in extended trading

** CTNM kicks off public offering of $75 million worth of shares

** Goldman Sachs, Leerink Partners, Stifel, RBC Capital Markets and William Blair are joint book-running managers for proposed offering

** Proceeds will be used to advance the development of its experimental drug, PIPE-791, and to fund research and development activities, among other purposes

** CTNM has 29.2 million outstanding shares for $365.4 million market cap, per LSEG data

** All seven brokerages covering the stock rate it "buy" or higher; median PT $22 — data compiled by LSEG

** As of last close, CTNM down 10.8% YTD

(Reporting by Arasu Kannagi Basil in Bengaluru)

((ArasuKannagi.Basil@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment